A large-scale method for T cell depletion: Towards graft engineering of mobilized peripheral blood stem cells

Bone Marrow Transplantation

Volumn 30, Issue 2, 2002, Pages 69-74

  Gordon, P R ^a   Leimig, T ^a   Mueller, I ^a   Babarin Dorner, A ^a   Holladay, M A ^a   Houston, J ^a   Kerst, G ^b   Geiger, T ^a   Handgretinger, R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Allogeneic transplantation; Clinimacs; Peripheral blood stem cells; T cell depletion

Indexed keywords

CD3 ANTIGEN; CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; CD133 ANTIGEN; GLYCOPROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; OKT 3; PEPTIDE;

ARTICLE; BIOENGINEERING; CELL SORTER; CONTROLLED STUDY; DONOR; FEASIBILITY STUDY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MONONUCLEAR CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; T LYMPHOCYTE; VOLUNTEER; ANIMAL; CELL SEPARATION; CYTOLOGY; GRAFT SURVIVAL; IMMUNOLOGY; IMMUNOMAGNETIC SEPARATION; METHODOLOGY; MOUSE; NONOBESE DIABETIC MOUSE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD34; CELL SEPARATION; FEASIBILITY STUDIES; GLYCOPROTEINS; GRAFT SURVIVAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOMAGNETIC SEPARATION; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED NOD; MUROMONAB-CD3; PEPTIDES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0036054063     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703619     Document Type: Article

References (32)

1. Allogeneic transplantation for advanced leukemia: Improved short-term outcome with blood stem cell grafts and tacrolimus
2. Allogeneic blood cell transplants for haematological malignancy: Preliminary comparison of outcomes with bone marrow transplantation
3. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation
4. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: First results of a randomised multicentre trial of the European Group for Marrow Transplantation
5. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human antigen-identical sibling transplantation
6. +) progenitor cells from HLA-mismatched parental donors in children
7. Treatment of high-risk acute leukemia with T cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
8. Standardization of T-cell depletion in HLA matched bone marrow transplantation
9. T cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T cell antibodies with narrow specificities
10. + cells using the CliniMACS device
11. + cells without prophylactic post-transplant immuno-suppression in adult patients with first chronic phase chronic phase II study
12. + stem cells from unrelated donors in children: Effective prevention of GVHD
13. + selected cells from an HLA haplo-identical related donor. A long-term follow-up of 135 patients and a comparison of stem cell source between the bone marrow and the peripheral blood
14. A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors
15. Effect of graft-versus-host disease on anti-tumor immunity
16. Donating stimulated peripheral blood stem cells vs bone marrow: Do donors experience the procedures differently?
17. Muromonab CD-3: A review of its pharmacology, pharmacokinetics, and clinical use in transplantation
18. Complement-mediated T-cell depletion of bone marrow: Comparison of T10B9.1A-31 and Muronomab-Orthoclone OKT3
19. Immunobiology of natural killer cells and bone marrow transplantation: Merging of basic and preclinical studies
20. Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in mice
21. Monocyte deactivation and its reversal in a patient with chemotherapy-induced leukopenia and severe systemic infection
22. Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta
23. NK cells and NKT cells in innate defense against viral infections
24. Analysis of in situ NK cell responses during viral infection
25. Long-term lymphohematopoietic reconstitution by a single CD34-low/negative hematopoietic stem cell
26. + cells
27. A newly discovered class of human hematopoietic cells with SCID-repopulating activity
28. Normal and leukemic CD34-negative human hematopoietic stem cells
29. +AC133+ cells isolated from cord blood are highly enriched in long-term culture-initiating cells, NOD/SCID-repopulating cells and dendritic cell progenitors
30. Epstein-Barr viru (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV lymphoproliferative disease following T-cell-depleted SCT
31. Adoptive cellular immunotherapy for EBV lymphoproliferative disease
32. Chimaeric anti-CD2 monoclonal antibody (rituximab) in post-transplant B-lympho-proliferative disorder following stem cell transplantation in children